In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Xoma licenses Baxter rights to Neuprex; ends agreement

Executive Summary

Xoma licensed Baxter Healthcare's Hyland Immuno division exclusive worldwide rights to its Neuprex, which has completed Phase III clinical trials for the treatment of meningococcemia. Baxter also gets rights to all future antibacterial and anti-endotoxin indications.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register